척수성 근위축증(SMA) 치료 시장 : 유형별, 투여 경로별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Spinal Muscular Atrophy Treatment Market," The spinal muscular atrophy treatment market was valued at $4.3 billion in 2022, and is estimated to reach $8.4 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032.

Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons, which are the nerve cells responsible for controlling voluntary muscle movements. It is characterized by the progressive degeneration of these motor neurons, leading to muscle weakness and atrophy. The symptoms of SMA can vary widely, but they generally involve muscle weakness and atrophy, difficulty with motor function, respiratory problems, and reduced mobility. The severity of the condition and the rate of disease progression can also vary among individuals.

The most widely used and effective treatment for spinal muscular atrophy is gene replacement therapy. One such therapy is called Onasemnogene abeparvovec (Zolgensma). It involves delivering a functional copy of the SMN1 gene (which is deficient in SMA) to motor neurons using a viral vector. This therapy has shown remarkable success in infants with SMA and has the potential to halt disease progression.

The major factors that drive the growth of the global spinal muscular atrophy treatment market include, increase in prevalence of spinal muscular atrophy. For instance, according to the Centers for disease Control and Prevention (CDC) in March 2023, spinal muscular atrophy (SMA) is a genetic disorder that affects approximately 1 out of every 10,000 people.

As more cases are diagnosed and reported, there is a growing patient population that requires effective treatment options. This increase in prevalence of SMA contributes to the expansion of the market growth. The introduction of disease-modifying therapies, such as Nusinersen and Onasemnogene abeparvovec, has revolutionized the treatment landscape for SMA. These therapies have shown significant clinical benefits and improved the prognosis for individuals with SMA, leading to increased demand for SMA drugs and propels the market growth.

In addition, improved understanding, and awareness of SMA among healthcare professionals and the public, there has been an emphasis on early diagnosis through genetic testing. Early detection allows for timely intervention and treatment initiation, which is driving the demand for SMA therapies. Another market driver is the growing recognition of rare diseases significance, rise in initiatives to raise SMA awareness, and increase in research efforts by market participants to develop effective treatments for SMA. However, high cost of the spinal muscular atrophy treatment limits the adoption of SMA drugs which restrain the market growth.

The global spinal muscular atrophy treatment market is segmented into type, route of administration, distribution channel, and region. By type, the market is categorized into type 1, type 2, and others. By route of administration, the market is bifurcated into oral and parenteral. By end user, the market is classified into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).

Major key players that operate in the global spinal muscular atrophy treatment market are Biogen, Beijing Jinlan Gene Technology Co., Ltd., Cytokinetics, F. Hoffmann-La Roche Ltd., Hanugen Theraputics, Ionis Pharmaceuticals, Inc. NMD PHARMA A/S, Novartis AG, Pfizer Inc., and Scholar Rock Holding Corporation. Key players operating in the market have adopted product approval, product launch, and agreement as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the spinal muscular atrophy treatment market analysis from 2022 to 2032 to identify the prevailing spinal muscular atrophy treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the spinal muscular atrophy treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global spinal muscular atrophy treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Type 1
• Type 2
• Others

By Route of Administration

• Oral
• Parenteral

By End User

• Hospitals
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East And Africa

Key Market Players:

• Beijing Jinlan Gene Technology Co., Ltd.
• Biogen
• Cytokinetics
• F. Hoffmann-La Roche Ltd.
• Hanugen Theraputics
• Ionis Pharmaceuticals, Inc.
• NMD Phrama A/S
• Novartis AG
• Pfizer Inc.
• Scholar Rock Holding Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Moderate bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. Moderate bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of spinal muscular atrophy
    • 3.4.1.2. Initiatives by government organizations
    • 3.4.1.3. Increase in the demand for drugs for the SMA

• 3.4.2. Restraints
  • 3.4.2.1. High cost of SMA drugs

• 3.4.3. Opportunities
  • 3.4.3.1. Increase in R&D activities

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Type 1
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Type 2
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Oral
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Parenteral
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospitals
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Others
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Route of Administration
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Type
    • 7.2.5.1.3. Market size and forecast, by Route of Administration
    • 7.2.5.1.4. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Type
    • 7.2.5.2.3. Market size and forecast, by Route of Administration
    • 7.2.5.2.4. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Type
    • 7.2.5.3.3. Market size and forecast, by Route of Administration
    • 7.2.5.3.4. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Route of Administration
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Type
    • 7.3.5.1.3. Market size and forecast, by Route of Administration
    • 7.3.5.1.4. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Type
    • 7.3.5.2.3. Market size and forecast, by Route of Administration
    • 7.3.5.2.4. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Type
    • 7.3.5.3.3. Market size and forecast, by Route of Administration
    • 7.3.5.3.4. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Type
    • 7.3.5.4.3. Market size and forecast, by Route of Administration
    • 7.3.5.4.4. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Type
    • 7.3.5.5.3. Market size and forecast, by Route of Administration
    • 7.3.5.5.4. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Type
    • 7.3.5.6.3. Market size and forecast, by Route of Administration
    • 7.3.5.6.4. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Route of Administration
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Type
    • 7.4.5.1.3. Market size and forecast, by Route of Administration
    • 7.4.5.1.4. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Type
    • 7.4.5.2.3. Market size and forecast, by Route of Administration
    • 7.4.5.2.4. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Type
    • 7.4.5.3.3. Market size and forecast, by Route of Administration
    • 7.4.5.3.4. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Type
    • 7.4.5.4.3. Market size and forecast, by Route of Administration
    • 7.4.5.4.4. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Type
    • 7.4.5.5.3. Market size and forecast, by Route of Administration
    • 7.4.5.5.4. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Type
    • 7.4.5.6.3. Market size and forecast, by Route of Administration
    • 7.4.5.6.4. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Route of Administration
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Latin America
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Type
    • 7.5.5.1.3. Market size and forecast, by Route of Administration
    • 7.5.5.1.4. Market size and forecast, by End User
    • 7.5.5.2. Middle East And Africa
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Type
    • 7.5.5.2.3. Market size and forecast, by Route of Administration
    • 7.5.5.2.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Biogen
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Cytokinetics
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Hanugen Theraputics
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
• 9.4. NMD Phrama A/S
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Key strategic moves and developments
• 9.5. Novartis AG
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. F. Hoffmann-La Roche Ltd.
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Pfizer Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Scholar Rock Holding Corporation
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Beijing Jinlan Gene Technology Co., Ltd.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Key strategic moves and developments
• 9.10. Ionis Pharmaceuticals, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments